Neuron23 Announces First-in-Human Dose in... - Cure Parkinson's

Cure Parkinson's

26,299 members • 27,658 posts

Neuron23 Announces First-in-Human Dose in Phase 1 Clinical Trial of its Best-in-Class Brain-Penetrant LRRK2 Inhibitor for Parkinsons Disease

2 years ago•1 Reply

NEU-723 has been shown in preclinical studies to have strong disease-modifying potential with a higher therapeutic index than other candidates in development

prnewswire.com/news-release...

Written by

Farooqji

To view profiles and participate in discussions please or .

Neuron23 Announces First-in-Human Dose in... - Cure Parkinson's

Cure Parkinson's

Neuron23 Announces First-in-Human Dose in Phase 1 Clinical Trial of its Best-in-Class Brain-Penetrant LRRK2 Inhibitor for Parkinsons Disease

Not what you're looking for?

You may also like...

BioVie announces treatment of 1st patient in Phase 2 clinical trial of NE3107,ERK inhibitor that selectively inhibits neuroinflammation

Annovis Bio Announces First Patient Dosed in Phase 3 Trial in Patients with Early Parkinson’s Disease

Annovis Bio Announces Approval for EU Clinical Trial Sites for the Phase 3 Study of Buntanetap for the Treatment of Parkinson's Disease

ANNOVIS BIO ANNOUNCES POSITIVE FDA NOTICE FOR BUNTANETAP PHASE 3 CLINICAL TRIAL IN PARKINSON'S DISEASE

ANNOVIS BIO ANNOUNCES POSITIVE FDA FEEDBACK FOR BUNTANETAP PHASE 3 CLINICAL DEVELOPMENT IN PARKINSON'S DISEASE (ANVS401)

Related Posts

Moderation team

Popular Posts